Immunizing at birth is safe and effective against severe pneumococcal disease

August 26, 2011, Wellcome Trust
Immunizing at birth is safe and effective against severe pneumococcal disease
Vaccinating children against the pneumococcus at birth is safe and primes the immune system against later infection, according to research published in the journal ‘Clinical Infectious Diseases’.

(Medical Xpress) -- Vaccinating children against the pneumococcus at birth is safe and primes the immune system against later infection, according to research published in the journal Clinical Infectious Diseases.

The study, carried out by researchers at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, working in collaboration with scientists at the UCL Institute of Child Health, indicates that immunising children within the first three days of life does not negatively affect their responses to a second or third dose of .

Babies born to HIV-negative mothers were given 7-valent pneumococcal at birth and then again at ten and 14 weeks of age. A second group received the vaccine at six, ten and 14 weeks, one of the schedules recommended by the World Health Organization (WHO).

The vaccine was found to be equally safe when administered to both groups. By 18 weeks the vaccine had induced a protective immune response in around nine out of ten infants in both groups. The researchers tested immune memory by giving a 'booster' vaccine at 36 weeks and found vigorous responses to the booster in both groups, indicating that inability to respond to a second or third dose of the vaccine (immune tolerance), a potential hazard of newborn vaccination, was not a problem in either group.

was estimated to cause 14.5 million episodes of illness and 826 000 deaths in children under the age of 5 years worldwide in the year 2000. The bacterium can cause illnesses including in the lungs, bacteraemia (infection of the blood) and meningitis.

More than half of these deaths occurred in Africa. In Kenya, the disease is common in toddlers aged under two years; 15 per cent of these disease episodes occur in the first two months of life, before babies are due to receive the first dose of the vaccine.

"The Kenya expanded immunisation programme has brought about huge for children in Kenya," explains Professor Fred Were, a neonatologist and National Chairman of the Kenya Paediatric Association. "However, the less-than-a-month-old babies remain the most at-risk population for many bacterial infections. This research shows that, in principle, we may be able to reach them earlier with an effective vaccine against pneumococcal disease."

Dr. Anthony Scott, a researcher with the KEMRI-Wellcome Trust Research Programme, adds: "While the results of this study are very encouraging, further research is required to establish whether the schedule negatively affects responses to other routine childhood vaccines and to explore whether the second and/or third doses can be delivered earlier."

Explore further: Clinical trial of malaria vaccine begins in Africa

More information: Scott JAG et al. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis 2011 24 August [epub].

Related Stories

Clinical trial of malaria vaccine begins in Africa

May 25, 2011
The vaccine, RTS,S, developed by GlaxoSmithKline (GSK) Biologicals and PATH Malaria Vaccine Initiative (MVI), is currently in phase III clinical trials and has previously reduced episodes of malaria in infants and young children ...

TB trial highlights challenges with introducing new vaccine into childhood immunization schedule

June 22, 2011
A new vaccine to combat tuberculosis is less effective at stimulating an immune response when administered to Gambian infants in combination with the routine immunisation schedule, according to clinical trial results published ...

Recommended for you

New study offers insights on genetic indicators of COPD risk

January 16, 2018
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who have low, but stable, lung function early in life, and those who are particularly at risk ...

Previous influenza virus exposures enhance susceptibility in another influenza pandemic

January 16, 2018
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, Canadian researchers are calling for more attention to exceptions to that rule.

Don't hold your nose and close your mouth when you sneeze, doctors warn

January 15, 2018
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors in the journal BMJ Case Reports.

New antifungal provides hope in fight against superbugs

January 12, 2018
Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant ...

Dengue takes low and slow approach to replication

January 11, 2018
A new study reveals how dengue virus manages to reproduce itself in an infected person without triggering the body's normal defenses. Duke researchers report that dengue pulls off this hoax by co-opting a specialized structure ...

Different strains of same bacteria trigger widely varying immune responses

January 11, 2018
Genetic differences between different strains of the same pathogenic bacterial species appear to result in widely varying immune system responses, according to new research published in PLOS Pathogens.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.